Literature DB >> 5170776

Modification of malignancy by 5-bromodeoxyuridine. Studies of reversibility and immunological effects.

S Silagi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5170776     DOI： 10.1007/BF02628269

Source DB:  PubMed          Journal:  In Vitro        ISSN： 0073-5655


× No keyword cloud information.
  15 in total

1.  The distribution and fate of bromodeoxyuridine and bromodeoxycytidine in the mouse and rat.

Authors:  J P KRISS; L REVESZ
Journal:  Cancer Res       Date:  1962-02       Impact factor: 12.701

2.  The reversible control of animal cell differentiation by the thymidine analog, 5-bromodeoxyuridine.

Authors:  A W Coleman; J R Coleman; D Kankel; I Werner
Journal:  Exp Cell Res       Date:  1970-02       Impact factor: 3.905

3.  Differentiation of normal and malignant cells.

Authors:  G B Pierce
Journal:  Fed Proc       Date:  1970 May-Jun

4.  A clonal study of the reversible inhibition of muscle differentiation by the halogenated thymidine analog 5-bromodeoxyuridine.

Authors:  J R Coleman; A W Coleman; E J Hartline
Journal:  Dev Biol       Date:  1969-06       Impact factor: 3.582

5.  Radiosensitization of malignant brain tumours with bromouridine (thymidine analogue).

Authors:  T Hoshino; K Sano
Journal:  Acta Radiol Ther Phys Biol       Date:  1969 Feb-Apr

6.  The loss of phenotypic traits by differentiated cells, V. The effect of 5-bromodeoxyuridine on cloned chondrocytes.

Authors:  J Abbott; H Holtzer
Journal:  Proc Natl Acad Sci U S A       Date:  1968-04       Impact factor: 11.205

7.  Metabolism of 1-beta-D-arabinofuranosylcytosine in L cells.

Authors:  S Silagi
Journal:  Cancer Res       Date:  1965-10       Impact factor: 12.701

8.  Hybridization of a malignant melanoma cell line with L cells in vitro.

Authors:  S Silagi
Journal:  Cancer Res       Date:  1967-11       Impact factor: 12.701

9.  Suppression of malignancy and differentiation in melanotic melanoma cells.

Authors:  S Silagi; S A Bruce
Journal:  Proc Natl Acad Sci U S A       Date:  1970-05       Impact factor: 11.205

10.  Inhibition of myoblast fusion after one round of DNA synthesis in 5-bromodeoxyuridine.

Authors:  R Bischoff; H Holtzer
Journal:  J Cell Biol       Date:  1970-01       Impact factor: 10.539
View more
  12 in total

1.  Effect of 5-bromodeoxyuridine on mouse myeloma cells.

Authors:  O S Pettengill; G D Sorenson
Journal:  In Vitro       Date:  1974 Nov-Dec

2.  The stability of the neoplastic state: introduction.

Authors:  H C Pitot
Journal:  Am J Pathol       Date:  1977-12       Impact factor: 4.307

3.  Correlated suppression by 5-bromodeoxyuridine of tumorigenicity and plasminogen activator in mouse melanoma cells.

Authors:  J K Christman; S Silagi; E W Newcomb; S C Silverstein; G Acs
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

4.  Tumorigenicity, immunogenicity, and virus production in mouse melanoma cells treated with 5-bromodeoxyuridine.

Authors:  S Silagi; D Beju; J Wrathall; E Deharven
Journal:  Proc Natl Acad Sci U S A       Date:  1972-11       Impact factor: 11.205

5.  Reversible suppression of malignancy and differentiation of melanoma cells.

Authors:  S Silagi
Journal:  Am J Pathol       Date:  1977-12       Impact factor: 4.307

6.  Histopathology and host response associated with reduced tumorigenicity of 5-bromodeoxyuridine--treated murine melanoma cells.

Authors:  K K Gyi; J R Wrathall
Journal:  Am J Pathol       Date:  1983-02       Impact factor: 4.307

7.  5-Bromodeoxyuridine-tolerant melanoma cells in vitro and in vivo.

Authors:  L M Pasztor; F Hu; W P McNulty
Journal:  Yale J Biol Med       Date:  1973-12

8.  Ultrastructural effects of thymidine analogs in melanosomes and virus activation in cloned hamster melanoma cells in culture.

Authors:  W L Epstein; K Fukuyama; T E Drake
Journal:  Yale J Biol Med       Date:  1973-12

9.  Changes in cytoarchitecture and mobility in B16F1 melanoma cells induced by 5-Br-2'-dU coincide with Rock2, miRNAs 138-5p and 455-3p reciprocal expressions.

Authors:  Esther Natalia Muñoz; Hernán Mauricio Rivera; Luis Alberto Gómez
Journal:  Biochem Biophys Rep       Date:  2021-06-11

10.  Leukocyte subpopulations elicited by a nontumorigenic variant of B16 melanoma: their role in direct rejection of the melanoma and in prevention of tumorigenesis in Winn assays.

Authors:  T A Calvelli; V H Freedman; S C Silverstein; S Silagi
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.